Final report of University Hospital Hradec Kralove to the clinical trial protocol no. PCYC-1130-CA

Abstract

A Randomized, Multi-center, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Subjects With Treatment-naïve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Keywords

• Ibrutinib
• Obinutuzumab
• Chlorambucil
• Treatment-naïve Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma